check the references on Grateful med re:cox 2 inhibitors--search medline --here is one of the published refs available to all::::Hope this helps
National Library of Medicine: IGM Full Record Screen
[Help] [show_loansome] [Log off IGM]
[Next Record] [infosearch_1] [Return to Results] [Return to Search Screen]
[Previous Record]
----------------------------------------------------------------------------
----------------------------------------------------------------------------
----------------------------------------------------------------------------
----------------------------------------------------------------------------
[FR_9751091]
TITLE: Preliminary study of the safety and efficacy of SC-58635,
a novel cyclooxygenase 2 inhibitor: efficacy and safety
in two placebo- controlled trials in osteoarthritis and
rheumatoid arthritis, and studies of gastrointestinal and
platelet effects.
AUTHORS: Simon LS; Lanza FL; Lipsky PE; Hubbard RC; Talwalker S;
Schwartz BD; Isakson PC; Geis GS
AUTHOR Beth Israel Deaconess Medical Center, Harvard Medical
AFFILIATION: School, Boston, Massachusetts 02215, USA.
SOURCE: Arthritis Rheum 1998 Sep;41(9):1591-602
CITATION IDS: PMID: 9751091 UI: 98421711
ABSTRACT: OBJECTIVE: To investigate the efficacy and safety of
SC-58635 (celecoxib), an antiinflammatory and analgesic
agent that acts by selective cyclooxygenase 2 (COX-2)
inhibition and is not expected to cause the typical
gastrointestinal (GI), renal, and platelet-related side
effects associated with inhibition of the COX-1 enzyme.
METHODS: Four phase II trials were performed: a 2-week
osteoarthritis efficacy trial, a 4-week rheumatoid
arthritis efficacy trial, a 1-week endoscopic study of GI
mucosal effects, and a 1-week study of effects on
platelet function. RESULTS: The 2 arthritis trials
identified SC- 58635 dosage levels that were consistently
effective in treating the signs and symptoms of arthritis
and were distinguished from placebo on standard arthritis
scales. In the upper GI endoscopy study, 19% of subjects
receiving naproxen (6 of 32) developed gastric ulcers,
whereas no ulcers occurred in subjects receiving SC-58635
or placebo. The study of platelet effects revealed no
meaningful effect of SC-58635 on platelet aggregation or
thromboxane B2 levels, whereas aspirin caused significant
decreases in 2 of 3 platelet aggregation measures and
thromboxane B2 levels. In all 4 trials, SC-58635 was well
tolerated, with a safety profile similar to that of
placebo. CONCLUSION: SC-58635 achieves analgesic and
antiinflammatory efficacy in arthritis through selective
COX-2 inhibition, without showing any evidence of 2 of
the toxic effects of COX-1 inhibition associated with
nonsteroidal antiinflammatory drugs.
MAIN MESH Arthritis, Rheumatoid/*drug therapy
HEADINGS: Cyclooxygenase Inhibitors/*therapeutic use
Osteoarthritis/*drug therapy
Sulfonamides/*therapeutic use
ADDITIONAL Adult
MESH HEADINGS: Aged
Aged, 80 and over
Aspirin/therapeutic use
Cyclooxygenase Inhibitors/adverse effects
Endoscopy
Female
Human
Knee Joint/drug effects
Knee Joint/pathology
Male
Middle Age
Naproxen/adverse effects
Platelet Aggregation/drug effects
Platelet Aggregation Inhibitors/therapeutic use
Safety
Severity of Illness Index
Stomach Ulcer/chemically induced
Stomach Ulcer/pathology
Sulfonamides/adverse effects
Support, Non-U.S. Gov't
Thromboxane B2/blood
Treatment Outcome
PUBLICATION CLINICAL TRIAL
TYPES: CLINICAL TRIAL, PHASE II
JOURNAL ARTICLE
MULTICENTER STUDY
RANDOMIZED CONTROLLED TRIAL
CAS REGISTRY 0 (Cyclooxygenase Inhibitors)
NUMBERS: 0 (Platelet Aggregation Inhibitors)
0 (Sulfonamides)
184007-95-2 (celecoxib)
22204-53-1 (Naproxen)
50-78-2 (Aspirin)
54397-85-2 (Thromboxane B2)
LANGUAGES: Eng
---------------------------------------------------------------------------
[Help] [show_loansome] [Log off IGM]
[Next Record] [infosearch_1] [Return to Results] [Return to Search Screen]
[Previous Record] |
